Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Xu, Jianming; Zhang, Yun; Jia, Ru; Yue, Chunyan; Chang, Lianpeng; Liu, Rongrui; Zhang, Gairong; Zhao, Chuanhua; Zhang, Yaoyue; Chen, Chunxia; Wang, Yan; Yi, Xin; Hu, Zhiyuan; Zou, Jianjun; Wang, Quanren

doi:10.1158/1078-0432.ccr-18-2484

Cited by 501Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Xu, Jianming, Zhang, Yun, Jia, Ru, Yue, Chunyan, Chang, Lianpeng, Liu, Rongrui, Zhang, Gairong, Zhao, Chuanhua, Zhang, Yaoyue, Chen, Chunxia, Wang, Yan, Yi, Xin, Hu, Zhiyuan, Zou, Jianjun, Wang, Quanren·2019·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-18-2484

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced hepatocellular carcinoma (HCC), gastric, or esophagogastric junction cancer (GC/EGJC). Patients and Methods: This was an open-label, dose-escalation (phase Ia) and expansion study (phase Ib). In phase Ia, patients (n = 15) received SHR-1210 200 mg every 2 weeks and apatinib 125–500 mg once daily until unacceptable toxicity or disease progression. In phase Ib, patients (n = 28) received apatinib at the phase Ia–identified recommended phase II dose (RP2D) plus SHR-1210. The primary objectives were safety and tolerability and RP2D determination. Results: At data cutoff, 43 patients were enrolled. In phase Ia, four dose-limiting toxicity events were observed (26.7%): one grade 3 lipase elevation (6.7%) in the apatinib 250 mg cohort and three grade 3 pneumonitis events (20%) in the apatinib 500 mg cohort. The maximum tolerated RP2D for apatinib was 250 mg. Of the 33 patients treated with the R2PD combination, 20 (60.6%) experienced a grade ≥3 treatment-related adverse event; adverse events in ≥10% of patients were hypertension (15.2%) and increased aspartate aminotransferase (15.2%). The objective response rate in 39 evaluable patients was 30.8% (95% CI: 17.0%–47.6%). Eight of 16 evaluable HCC patients achieved a partial response (50.0%, 95% CI: 24.7%–75.4%). Conclusions: SHR-1210 and apatinib combination therapy demonstrated manageable toxicity in patients with HCC and GC/EGJC at recommended single-agent doses of both drugs. The RP2D for apatinib as combination therapy was 250 mg, which showed encouraging clinical activity in patients with advanced HCC.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-2484

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, STING agonist, FMT, epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity.
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [22]
Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305, camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers.
“Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305 (bevacizumab biosimilar), camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers [22, 114–120].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [22]

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,725
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Wilke, H., Muro, K., Cutsem, E. V., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,477
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Kang, Y., Boku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,273
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,627
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 975
Self-citation
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J. F., Han, G., Schalper, K. A., Carvajal‐Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R. S., LoRusso, P. M., & Rimm, D. L. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 845
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M. D., Harview, C. L., Taube, J. M., Handley, N. R., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0325 · Cited by 582
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M. J. P., Mazumdar, C., Schmidt, L., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 372
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M. B., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 345
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Tartour, É., Péré, H., Maillère, B., Terme, M., Merillon, N., Taı̈eb, J., Sandoval, F., Quintin‐Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 324
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang, Y., Xu, R.-H., Chin, K., Lee, K.-W., Park, S., Rha, S., Shen, L., Qin, S., Xu, N., Im, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30682-4 · Cited by 270
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
Fuchs, C. S., Doi, T., Jang, R. W.-J., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4003 · Cited by 173
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
Yue, C., Jiang, Y., Li, P., Wang, Y., Xue, J., Li, N., Li, D., Wang, R., Dang, Y., Hu, Z., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438111 · Cited by 157
Self-citation
Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors
Scott, A. J., Messersmith, W., & Jimeno, A. (2015) · Drugs of today · doi:10.1358/dot.2015.51.4.2320599 · Cited by 145
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Stein, S., Pishvaian, M. J., Lee, M. S., Lee, K.-H., Hernandez, S., Kwan, A., Liu, B., Grossman, W., Iizuka, K., & Ryoo, B. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4074 · Cited by 111
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma
Guislain, A., Gadiot, J., Kaiser, A., Jordanova, E. S., Broeks, A., Sanders, J., van Boven, H., de Gruijl, T. D., Haanen, J. B. A. G., Bex, A., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1735-z · Cited by 105
Clinical applications of PD-L1 bioassays for cancer immunotherapy
Liu, D., Wang, S., & Bindeman, W. E. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0479-y · Cited by 86
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
Chowdhury, S., McDermott, D. F., Voss, M. H., Hawkins, R. E., Aimone, P., Voi, M., Isabelle, N., Wu, Y.-L. L. C., & Infante, J. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4506 · Cited by 84
Circulating tumour cells and cell-free DNA in gastrointestinal cancer
Pantel, K., & Alix‐Panabières, C. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.198 · Cited by 68
Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.
Qin, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4019 · Cited by 66
Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
Turcotte, S., Gros, A., Tran, E., Lee, C. R., Wunderlich, J. R., Robbins, P. F., & Rosenberg, S. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1736 · Cited by 63
Efficacy of PD-1 Blockade in Tumors with MMR Deficiency
Lee, V., & Le, D. T. (2015) · Immunotherapy · doi:10.2217/imt.15.97 · Cited by 48
OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer
Zhao, S., Jiang, T., Li, X., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.293 · Cited by 12
Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
Huang, J., Mo, H., Wu, D., Chen, X., Ma, L., Lan, B., Dong, Q., Yang, Q., & Xu, B. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e15572 · Cited by 9

Flagged first, then by citations

1 of the 46 references couldn’t be matched to a known paper.

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Targeted therapy for hepatocellular carcinoma
Huang, A., Yang, X., Chung, W. Y., Dennison, A. R., & Zhou, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00264-x · Cited by 767
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Self-citation
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 604
Self-citation
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Huang, J., Xu, J., Chen, Y., Zhuang, W., Zhang, Y., Chen, Z., Chen, J., Zhang, H., Niu, Z., Fan, Q., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30110-8 · Cited by 592
Self-citation
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2571 · Cited by 567
Self-citation
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, A., Hsu, C., Chan, S. L., Choo, S.-P., & Kudo, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.025 · Cited by 529
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 505
Self-citation
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528
Antibodies to watch in 2019
Kaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 435
Advances in clinical immunotherapy for gastric cancer
Li, K., Zhang, A., Li, X., Zhang, H., & Zhao, L. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188615 · Cited by 407
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 323
Self-citation
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Self-citation
Camrelizumab: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01167-0 · Cited by 267
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 269
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 245
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Pan, C.-X., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 248
Esophageal cancer in China: Practice and research in the new era
Zhu, H., Ma, X., Ye, T., Wang, H., Wang, Z., Liu, Q., & Zhao, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.34301 · Cited by 241
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
Zhu, X., Huang, C., Shen, Y., Ji, Y., Ge, N., Qu, X.-D., Chen, L., Shi, W.-K., Li, M., Zhu, J., et al. (2021) · Liver Cancer · doi:10.1159/000514313 · Cited by 235
Recent advances in systemic therapy for hepatocellular carcinoma
Zhang, H., Zhang, W., Jiang, L., & Chen, Y. (2022) · Biomarker Research · doi:10.1186/s40364-021-00350-4 · Cited by 218
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Lan, C., Shen, J., Wang, Y., Li, J., Liu, Z., He, M., Cao, X., Ling, J., Huang, J., Zheng, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01920 · Cited by 210
Self-citation
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
Luo, X., Wu, K., & He, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01968-w · Cited by 207
Trial watch: IDO inhibitors in cancer therapy
Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 192
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183
Self-citation
Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
Zhang, M., Huang, L.-F., Ding, G., Huang, H., Cao, G., Sun, X. D., Lou, N., Wei, Q., Shen, T., Xu, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000308 · Cited by 171
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Song, Y., Wu, J., Chen, X., Lin, T., Cao, J., Liu, Y., Zhao, Y., Jin, J., Huang, H., Hu, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1680 · Cited by 150
Self-citation
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Ou, D., Chen, C.-W., Hsu, C., Chung, C., Feng, Z.-R., Lee, B.-S., Cheng, A., Yang, M., & Hsu, C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001657 · Cited by 148
Self-citation
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
Mandlik, D. S., Mandlik, S. K., & Choudhary, H. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.1054 · Cited by 144
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
Wang, F., Qin, S., Sun, X., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00886-2 · Cited by 140
Self-citation
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J., Popel, A. S., Anders, R. A., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01218-y · Cited by 140
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.002 · Cited by 135
Self-citation
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
Ju, W., Xia, R., Zhu, D., Dou, S., Zhu, G., Dong, M., Wang, L., Sun, Q., Zhao, T., Zhou, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33080-8 · Cited by 143
Immune Checkpoint Inhibitors in the Treatment of HCC
Donisi, C., Puzzoni, M., Ziranu, P., Lai, E., Mariani, S., Saba, G., Impera, V., Dubois, M., Persano, M., Migliari, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.601240 · Cited by 133
Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer
Qiu, X., Qu, Y., Guo, B., Zheng, H., Meng, F., & Zhong, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.002 · Cited by 122
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 120
Self-citation
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Zhao, H., Yao, W., Min, X., Gu, K., Yu, G., Zhang, Z., Cui, J., Miao, L., Zhang, L., Yuan, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.006 · Cited by 120
Self-citation
Emerging agents and regimens for hepatocellular carcinoma
Zhu, X., & Sun, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0794-6 · Cited by 117
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial
Meng, F., Zhao, J., Tan, A. T., Hu, W., Wang, S., Jin, J., Wu, J., Li, Y., Shi, L., Fu, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10250-2 · Cited by 116
Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
Li, B., Yan, C., Zhu, J., Chen, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., Zhao, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01037 · Cited by 111
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Shao, Y., Wang, S.-Y., Lin, S., Chen, K.-Y., Tseng, J., Ho, M., Lee, R., Liang, P., Liao, L., Huang, K., et al. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.10.031 · Cited by 114
Self-citation
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 114
Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy
Sun, Y., Ma, W., Yang, Y., He, M., Li, A., Bai, L., Yu, B., & Yu, Z. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.04.005 · Cited by 115
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Peng, Z., Wei, J., Feng, W., Ying, J., Deng, Y., Gu, K., Cheng, Y., Yuan, X., Xiao, J., Tai, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4691 · Cited by 112
Self-citation
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study
Zhang, W., Yan, C., Zhang, T., Chen, X., Dong, J., Zhao, J., Han, D., Wang, J., Zhao, G., Cao, F., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1971418 · Cited by 111
Self-citation
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Wang, Y., Du, J., Gao, Z., Sun, H., Mei, M., Wang, Y., Ren, Y., & Zhou, X. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02084-y · Cited by 118
Self-citation
Targeting angiogenesis for liver cancer: Past, present, and future
Zhu, X., Tang, Z., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.03.010 · Cited by 105
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
Saeed, A., Park, R., & Sun, W. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01034-0 · Cited by 106
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 115
Self-citation
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Wang, Q., Gao, J., Di, W. J., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02576-x · Cited by 103
Self-citation
Evolution of Systemic Therapy for Hepatocellular Carcinoma
Finn, R. S., & Zhu, A. X. (2020) · Hepatology · doi:10.1002/hep.31306 · Cited by 97
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
Jin, Z., Zhong, B., Chen, J.-J., Zhu, H., Sun, J., Yin, G., Ge, N., Luo, B., Ding, W., Li, W., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09754-2 · Cited by 97
Self-citation
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
Cheng, H., Zong, L., Kong, Y., Wang, X., Gu, Y. L., Cang, W., Zhao, J., Wan, X., Yang, J., & Xiang, Y. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00460-5 · Cited by 91
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy
Shi, J., Liu, J., Tu, X., Li, B., Tong, Z., Wang, T., Zheng, Y., Shi, H., Zeng, X., Chen, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003133 · Cited by 90
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Leone, P., Solimando, A. G., Fasano, R., Argentiero, A., Malerba, E., Buonavoglia, A., Lupo, L., Re, V. D., Silvestris, N., & Racanelli, V. (2021) · Vaccines · doi:10.3390/vaccines9050532 · Cited by 88
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Meng, X., Wu, T., Hong, Y., Fan, Q., Ren, Z., Guo, Y., Yang, X., Shi, P., Yang, J., Yin, X., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00378-2 · Cited by 88
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
Chen, C., Gu, Y., Zhang, F., Zhang, Z.-C., Zhang, Y., He, Y.-D., Wang, L., Zhou, N., Tang, F., Liu, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1901434 · Cited by 87
Self-citation
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Federico, P., Petrillo, A., Giordano, P., Bosso, D., Fabbrocini, A., Ottaviano, M., Rosanova, M., Silvestri, A., Tufo, A., Cozzolino, A., et al. (2020) · Cancers · doi:10.3390/cancers12103025 · Cited by 83
Mechanisms of angiogenesis in tumour
Zhang, R., Yao, Y., Gao, H., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1359069 · Cited by 90
MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents
Yang, B., Wang, C., Xie, H., Wang, Y., Huang, J., Rong, Y., Zhang, H., Kong, H., Yang, Y., & Lu, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2023-1 · Cited by 77
Self-citation
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
Ding, X., Zhang, W., You, R., Zou, X., Wang, Z., Ouyang, Y., Peng, L., Liu, Y., Duan, C., Yang, Q., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01450 · Cited by 76
Environmental eustress modulates β-ARs/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice
Liu, C., Yang, Y., Chen, C., Li, L., Li, J., Wang, X., Chu, Q., Qiu, L., Ba, Q., Li, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25967-9 · Cited by 74
Self-citation
Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study
Zhang, J., Zhang, X., Mu, H., Yu, G., Xing, W., Wang, L., & Zhang, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.729764 · Cited by 73
Immunotherapies for hepatocellular carcinoma
Liu, J. K. H., Irvine, A. F., Jones, R. L., & Samson, A. (2021) · Cancer Medicine · doi:10.1002/cam4.4468 · Cited by 72
Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options
Ghavimi, S., Apfel, T., Azimi, H., Persaud, A., & Pyrsopoulos, N. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00001 · Cited by 72
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
Liu, B., Gao, S., Zhu, X., Guo, J., Kou, F., Liu, S.-X., Zhang, X., Wang, X.-D., Cao, G., Chen, H., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0192 · Cited by 72
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
Mei, K., Qin, S., Chen, Z., Liu, Y., Wang, L., & Zou, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002191 · Cited by 70
Self-citation
Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma
Liao, J., Jin, H., Li, S., Xu, L., Peng, Z., Wei, G., Long, J., Guo, Y., Kuang, M., Zhou, Q., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1419-1 · Cited by 68
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Aziz, M. A. A. E., Facciorusso, A., Nayfeh, T., Saadi, S. M., Elnaggar, M. Y., Cotsoglou, C., & Sacco, R. (2020) · Vaccines · doi:10.3390/vaccines8040616 · Cited by 65
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial
Lin, J., Tang, Y.-H., Zheng, H., Ye, K., Cai, J., Cai, L., Lin, W., Xie, J., Wang, J.-B., Lü, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44309-5 · Cited by 65
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Sun, Y., Zhang, W., Bi, X., Yang, Z., Tang, Y., Jiang, L., Bi, F., Chen, M., Cheng, S., Chi, Y., et al. (2022) · Liver Cancer · doi:10.1159/000521596 · Cited by 61
Self-citation
Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
Zheng, H., Guo, B., Qiu, X., Xia, Y., Qu, Y., Cheng, L., Meng, F., & Zhong, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.029 · Cited by 62
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Fan, Y., Xue, H., & Zheng, H. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s358082 · Cited by 65
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
Feng, Y., Chan, L. L., & Chan, S. L. (2022) · Current Oncology · doi:10.3390/curroncol29080434 · Cited by 61
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Liu, L., Wen, T., Kuang, M., Zhang, B., et al. (2025) · Liver Cancer · doi:10.1159/000546574 · Cited by 78
Self-citation
Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Mei, J., Li, S., Li, Q., Sun, X., Lu, L., Lin, W., Zheng, L., Chen, M., Shi, M., Wei, W., et al. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s298538 · Cited by 59
Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma
Xu, M., Liu, Y., Lin, Y., Lu, Y., Bi, X., Jiang, T., Deng, W., Zhang, L., Yi, W., Xie, Y., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01615-2 · Cited by 62
Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
Zhou, Y., Guo, Y., Chen, L., Zhang, X., Wu, W., Zhi-min, Y., Li, X., Wang, Y., Hu, Z., & Wang, Z. (2022) · Theranostics · doi:10.7150/thno.73104 · Cited by 60
Self-citation
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Lee, H. W., Cho, K. J., & Park, J. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e11 · Cited by 57
Advances of Targeted Therapy for Hepatocellular Carcinoma
Niu, M., Yi, M., Li, N., Wu, K., & Wu, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719896 · Cited by 57
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Li, Y., Jia, G.-D., Lv, X., Xie, S., Guo, S.-S., Lin, D.-F., Liu, L., Luo, D., Li, Y., Deng, S.-W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40402-x · Cited by 59
Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma
Gabbia, D., & Martin, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043441 · Cited by 54
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Zhang, W., Gong, C., Peng, X., Bi, X., Sun, Y., Zhou, J., Wu, F., Zeng, H., Wang, Y., Zhou, H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3972 · Cited by 53
Self-citation
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
Hsu, C., Rimassa, L., Sun, H., Vogel, A., & Kaseb, A. O. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211031141 · Cited by 51
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
Xu, Y., Huang, Z., Lu, H., Yu, X., Li, Y., Li, W., Chen, J., Chen, M., Gong, L., Chen, K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0583-6 · Cited by 49
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Cai, X., Wei, B., Li, L., Chen, X., Liu, W., Cui, J. T., Lin, Y., Sun, Y., Xu, Q., Guo, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106858 · Cited by 51
Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial
Chen, X., Qin, S., Gu, S., Ren, Z., Chen, Z., Xiong, J., Liu, Y., Meng, Z., Zhang, X., Wang, L., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33751 · Cited by 50
Self-citation
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
Jing, C., Wang, J., Zhu, M., Bai, Z., Baoyi, Z., Zhang, J., Yin, J., Yang, X., Liu, Z. Z., Zhang, Z., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03174-9 · Cited by 50
Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies
Tan, Z.-L., Yue, C., Ji, S., Zhao, C., Jia, R., Zhang, Y., Liu, R., Li, D., Yu, Q., Li, P., et al. (2021) · The Oncologist · doi:10.1002/onco.13981 · Cited by 49
Self-citation
Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Hu, Y., Zhou, M., Tang, J. P., Li, S., Liu, H., Hu, J., Ma, H., Liu, J., Qin, T., Yu, X., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2592 · Cited by 47
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
Chen, J., Hu, X., Li, Q., Dai, W., Cheng, X., Huang, W. M., Yu, W., Chen, M., Guo, Y., & Yuan, G. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6063 · Cited by 45
Retracted
αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
Fang, J., Ding, N., Guo, X., Sun, Y., Zhang, Z., Xie, B., Zhong, L., Wang, H., Mao, W., Lin, Z., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001162 · Cited by 47
Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
Luo, Q., Dong, Z., Xie, W., Fu, X., Lin, L., Zeng, Q., Chen, Y., Ye, G., Chen, M., Hu, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112437 · Cited by 46
Immune Therapy for Liver Cancers
Hilmi, M., Vienot, A., Rousseau, B., & Neuzillet, C. (2019) · Cancers · doi:10.3390/cancers12010077 · Cited by 46
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma
Kim, E. J., Yoo, C., Kang, H. J., Kim, K., Ryu, M., Park, S. R., Lee, D., Choi, J., Shim, J. H., Kim, K. M., et al. (2021) · Liver International · doi:10.1111/liv.14813 · Cited by 46
Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
Li, S., Zhang, Q., & Hong, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980116 · Cited by 52
Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
Li, H., Huang, H., Zhang, T., Feng, H., Wang, S., Zhang, Y., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937307 · Cited by 46
Self-citation
Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 52
Anti-angiogenesis: Opening a new window for immunotherapy
Guo, F., & Cui, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118163 · Cited by 46

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.
Xu, J., Zhang, Y., Jia, R., Wang, Y., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Zou, J., & Wang, Q. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4075 · Cited by 24
Self-citation
Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial.
Zhao, H., Zhao, J., Jiang, L., Bi, X., Qian, H.-G., Du, S., Cai, J., Zhou, J., Li, Z., Liu, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.285 · Cited by 3
Self-citation
724P Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial
Zhao, H.-Y., Du, S., Zhu, Z., Jiang, L., Che, X., Qian, H., Song, J., Liu, D., Zhang, Y., Zhang, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.848 · Cited by 2
Self-citation
Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib
Zhang, Z., Zhou, Y., Hu, K., Li, Z., Wang, Z., & Huang, Y. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.07.005 · Cited by 9
A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Yan, S., Zhang, Y., Bi, X., Zhao, J., Du, S., Huang, Z., Zhang, Y., Liu, D., Li, Z., Zhou, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz438.022
Self-citation

Authors: Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., Wang, Y., Yi, X., Hu, Z., Zou, J., & Wang, Q.
Affiliations: 1Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Academy of Military Medical Sciences (CN)
Chinese Academy of Sciences (CN)
3Geneplus-Beijing Institute, Beijing, China.
Jiangsu Hengrui Medicine (China) (CN)
ORCID: Jia, Ru
Yue, Chunyan
Chang, Lianpeng
Liu, Rongrui
Wang, Yan
Yi, Xin
Hu, Zhiyuan
Zou, Jianjun
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2019-01-15
Volume: 25
Issue: 2
Pages: 515-523
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-18-2484
OpenAlex: W2897612290
Cited by: 498
References: 46
Citations by year: 2026: 19 · 2025: 33 · 2024: 67 · 2023: 69 · 2022: 109 · 2021: 91 · 2020: 82 · 2019: 26
FWCI: 18.90
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Jiangsu Hengrui Medicine Co. Ltd.
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: pembrolizumab, anti-PD-1, apatinib, VEGFR-2 inhibitors, combination immunotherapy, hepatocellular carcinoma, gastric cancer, gastroesophageal junction cancer, dose-limiting toxicity, pneumonitis, lipase elevation, recommended phase 2 dose, objective response rate
MeSH terms: Antineoplastic Agents, Immunological, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Prognosis, Pyridines, Stomach Neoplasms, Biomarkers, Treatment Outcome, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks